At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Lovaza +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Placebo Controlled Trial of Omega-3 Fatty Acids in HIV Infected Subjects to Modulate Cardiovascular Risk
University Hospitals Cleveland Medical Center·interventional·Posted Oct 27, 2009·Updated Jan 7, 2015
In Brief
A Phase 2 clinical trial evaluating Lovaza and Placebo for HIV Infections and Heart Disease. Completed, enrolled 35 participants across 1 site.
Detailed Summary
Several studies have shown that there is an increased risk of heart disease in people with HIV. In this study the investigators are looking at the effect of Lovaza (Omega-3 fatty acid) on improving endothelial function and decreasing inflammation which may contribute to this increased risk. The investigators will also be doing studies to analyze coagulation and inflammation markers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Heart Disease
CountriesUnited States
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedOct 2009
Primary CompletionMar 2010
Study CompletionJun 2010
TodayJul 2026
First PostedOct 27, 2009
Enrollment StartApr 1, 2009
Primary CompletionMar 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.7 years ago
Interventions
Lovazadrug
Lovaza one gram twice a day for 24 weeks
Placebodrug
Placebo